Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The reviews for Vitastem are overwhelmingly positive on Amazon.
The scenario presented in the July 2018 shareholders newsletter versus what Todd is saying seem like two entirely different companies
Has anyone besides slops ever tried to call IR and ask questions? What is the phone number?
Is this company doing anything at this time? At one point they had a raspberry wonder cannabis infused beverage. I bought a case of it and thought it had potential. It had a hemp derivative in the drink. It did not advertise CBD specifically however which is what the consumer would be looking for today. THC drinks are also possible to do but that would be a different regulated market.
Is it still possible for this company to do something in the cannabis infused beverage market?
Bud-Life was going to be ready for the California Rec Market in January 2018. This is now November 2018. What actually happened to Bud-Life? It seemed to me like a real big potential money maker.
Tapping on the door of a 4 handle. Small investor sentiment seems to be a little bit subdued. Nobody has mentioned Libigel in a while. Corticotropin. A potential blockbuster also. Nobody seems to care.
Coca Cola wants to get into the Cannabis Beverage business. Perhaps they could buy out GRSU for a few measly billion dollars.
Hey Jeffqdhsr,
What is the best telephone number to reach Art Pryzbyl at? My email is tomhilsen@yahoo.com if you do not want to post it for the whole board to see. Any other questions that people want me to ask please post them. Thanks Jeff.
Catty I think that the CVRs will expire if no deal gets done by some future date. I have a few other questions that come to mind.
1) There are 4 million prescriptions for low dose testosterone given to women that are filled by compounding pharmacies. Why can we not manufacture this for these patients without making any claims at all about efficacy? It is just testosterone which is well known and now proven safe.
2) Why did investor relations ignore numerous questions from shareholders about the status of Libigel?
3) Does Art Pryzbyl think that a 70% reduction in CV incidents in women is medically significant?
The reason that we shareholders were having such a hard time getting a handle on what was happening with Libigel was that we were getting no information. Art is willing to talk. We need to ask him all of our questions.
JTFM is my choice to do the phone call if he is willing. He knows the most of any of us. He could record it and then transcribe it for the board members to see. If Libigel gets stolen from us we will have a better case if we can nail down what is really happening.
If JTFM is unwilling then I will do the call.
We need first to compile a list of all of our questions. Feel free to post Libigel questions here on this board.
To summarize the Libigel situation after reading the little information shared of Jeffq’s discussion with our CEO Pryzbyl . it seems that we can now say that the C camp were the correct thinkers about Libigel. There is no non -disclosure agreement. Libigel is mostly dead but not yet perhaps a funeral. Jon20 had the clear headed view. Pryzbyl called the discussion on this board about Libigel as misguided. That means that the A campers were misguided. I didn’t know that I could of just called the CEO with my questions regarded what was going on with Libigel all these years.
One question remains for me though? Why not inform the shareholders with any information regarding Libigel and the patent claim of 70% reduction in cardiovascular incidence shown in the large safety trial? I guess we can all just call the CEO if we want to know any and all information. Does the medical community care about this?
A Libigel Confidence Poll may be a curious interest for this active board that goes back to Biosante days.
Who here thinks that Libigel is :
A) Alive and has Blockbuster potential.
B) 50/50 or unknowable or a toss up.
C) Clearly a dead horse after 6 years of no mention and a nearly abandoned patent application.
You can also be between A and B or between B and C.
Please state when you first bought a stake in Biosante or ANIP.
I will start and say that I am currently between A and B. I bought Biosante before the Phase 3 failure and then doubled down after the failure. I think it was 2011 or 2012 when I first got long. I am amazed that JTFM is so diligent in his or her research. And there are others here who have remained faithful or duped for a very long time. I see the large market potential for Libigel and cannot let it go. Corticotropin and all the other drugs show solid earnings potential as well.
10,000 shares of buying volume in the last 5 minutes is a little bit unusual when it was 50,000 shares for the whole day.
We have a revenue of $1,022,000 per employee. That seems pretty high. We have 11.8 million outstanding shares. Our market cap is around $729 million.
What would prevent a big player from buying ANIP shares? If they bought 6 million shares they would assumably be in control. That is pocket change in the Pharma world.
Other than for those who are short ANIP I do not see the rational interest in keeping the share price down to 50% of it’s intrinsic value.
Thanks JTFM,
ANIP may be the most difficult stock for retail investors to figure out. The flow of information is what is valuable. Nondisclosure agreements and No Act filings seem to me like mechanisms to thwart retail investors from being able to make informed investment decisions. The SEC should be opposed to these sorts of manipulations if they cared about fairness.
I doubt whether any hedge fund has done the degree of due diligence that JTFM has done on ANIP. It would be too hard for them to do.
70% reduction in CV events with the side effect of increased libido. 4 million current users who resort to compounding pharmacies for the product. I would think that some heavy hitter other than we 6 or 7 small fry would show an interest.
I am not familiar with NO Act filings. Abbvie is perhaps able to keep secret material discoveries or legal or financial actions for some anti-competitive reason. Can anyone here expound on what are the potential implications of No Act SEC filings by Abbvie in the past several years and none yet for 2018. Thanks.
ANIP is flying under the radar. The intrinsic value is double what the stock price is at. Simply Wall Street did an analysis of discounted future earnings that shows this fact. This is with no regard for Corticotropin or for Libigel. Both of these drugs could be blockbusters and are not even considered.
JTFM has assembled an interesting detective story about Libigel that taken in it’s totality is compelling. I wonder whether it might be worthwhile to let some heavy hitters in on the story. Steven Cohen, David Tepper or Bill Ackman are in the business of looking for undervalued stocks to invest in. They employ large numbers of intelligent staff members who get paid to do extensive due diligence.
If we were to let the cat out of the bag it could have a big upside effect on our stock price. I think most of us are long here and would favor an upward movement in the PPS. Perhaps they already know what we know but perhaps not.
Analysts are expecting earnings of $ 1.19 per share for Q1 2018 reporting on May 3. The yoy earnings growth will be around 60% and yoy revenue growth should come in around 35%. The current stock price is discounted by around 50% off of it’s intrinsic (fundamental) value.
Daily volume has been abnormally low every day for the past month or two. Nobody loves ANIP and nobody cares about fundamentals or growth prospects. Something just does not add up.
Perhaps with Trump promising to lower drug prices investors have given up all hope for a prosperous future for the pharmaceutical sector.
Perhaps the abnormally large percentage of institutional holders has convinced retail investors that retail investors will get screwed somehow. There is a report about a make whole vulture capital toxic financing deal that benefits an institution if the stock price stays low. The lower the price the more shares they get to accumulate.
I wonder if anyone else has any idea why ANIP remains so undervalued.
So if Jon20ABX has been told by investor relations that all gel hormone products have been written off then we can assume perhaps that Libigel is indeed dead. I am not sure that all investors have this certain knowledge at this time. Does there need to be a dollar amount written off on the balance sheet for this loss? Will we see this on May 3 when they announce Q1 2018 earnings? Does the NDA still apply if it is dead?
I wonder whether all the secrecy surrounding Libigel rises to the level of criminality. Perhaps a securities lawyer could take on this one issue on a contingency basis. It might cost us nothing up front. The law firm would get paid out of the penalties collected
The volume has been abnormally low for the past month or so. Average daily volume is 134k. The market closes in 30 minutes and our volume so far today is 34k. CEO Pryzybyl recently sold 25,000 shares. He must have spread that out over several days or else it would have tanked our stock.
Thanks JTFM. The due diligence that you perform and share with us is the most thorough work that I have seen on any stock board. We are so lucky to have you.
If there is an NDA in place and that is the reason that we get no information, can the company simply acknowledge that there is an NDA. Is the existence itself of an NDA required to be a secret as well? How long would an NDA be in force typically? Should ANIP be receiving payment for providing an NDA?
The patent application will be considered to be abandoned today. The data for CV and breast cancer risk reduction is owned by Abbie. If they were to sell that data to a third party can they do an end run around ANIP shareholders?
Thanks so much for all that you do for us shareholders.
JTFM,
You have mentioned that Simes outright lied to you about collecting efficacy data during the large safety trial. Can you expound on that and what it means. If one were to imagine some sort of motive, can you imagine what that motive might be , hypothetically?
In what way does all the secrecy benefit the ANIP shareholders or the previous BPAX shareholders? Why do an NDA if it is better for the stock price if investors can see a strategy toward approval and a marketable product?
The secrecy would benefit outside interests at the expense of shareholders. There would need to have been a consideration given for that benefit that betrays shareholders. Simes himself was a large shareholder.
We shareholders made out really well after the merger with ANIP. No harm no foul perhaps. There still remains a mystery to me. I am glad that JTFM would not let it be swept under the rug.
If it is all really dead then it deserves a formal burial.
The Libigel story is among the ultimate intriquing stories in investigative biopharma investing. JTFM will deserve a prize similar to a Pulitzer Prize for investigative reporting if this all pans out.
What I wonder about is the status of the shareholder’s rights to know material things about his or her investment and whether that right to know has been violated with 6 years of secrecy regarding a potentially blockbuster product.
It all seems like testing the patience of investors to the extreme in a cruel and unusual way when uncertainty and lack of information lead to anxiety and risk off sentiments.
I would like to add a comment on the issue of the insider sales. Arthur Przbyl who is our CEO sold something in the area of 25,000 shares for a dollar amount of around 1.5 million dollars. It was about 13% of his personal ANIP holdings. He also sold options but I didn’t see the dollar amount. Perhaps this is not a large sale in the greater perspective of what he still has invested in the company.
The other director sales were maybe a quarter of these amounts.
Maybe this is normal and not all that negative.
If I were to sell 13% of my holding in any particular position I would consider that a small sale.
Simply Wall Street has a new report out on ANIP. Intrinsic value is deemed to be 114 pps upon evaluating future cash flow to a discounted present value. It is therefore currently 47% undervalued. This degree of a mismatch between the price for a stock and its underlying value is rare.
On the negative side are recent large insider sales and a negative political atmosphere for the pharmaceutical industry.
I read the recent Zacks article. Thanks lltd. What is odd is that we are now a value play. Next quarter’s earnings Q1’18 to be reported on May 3 is estimated on average to show 50% yoy earnings growth. When doing a valuation of a stock’s “fair value” it matters what we are looking at in terms of earnings growth. Corticotropin and Libigel seem to have very little value for this company. Libigel reduces Cardiovascualar death in women by 70%. Nobody cares. It is likely that HSDD is helped in women. Nobody cares. Word of Breast Cancer reduction as well with low dose testosterone. Nobody cares.
Forgetting all these speculations. On the fundamentals of what ANIP has already done in terms of actual products and sales the stock price seems to me to be undervalued. It has been reported that Wells Fargo and other institutional investors have a perverse vulture financing deal whereby they benefit proportionally by how much the stock price is below 69.73 in a make whole agreement. Could this be the reason we shareholders see limited appreciation over extended periods of time? It all seems a bit odd to me.
What is the fundamental value(fair value) of ANIP if one were to multiply an intermediate to long term earnings growth rate times an expected 2018 earnings of perhaps $5.75?